EP1613732A4 - Complexes intracellulaires utilises comme biomarqueurs - Google Patents

Complexes intracellulaires utilises comme biomarqueurs

Info

Publication number
EP1613732A4
EP1613732A4 EP20040758577 EP04758577A EP1613732A4 EP 1613732 A4 EP1613732 A4 EP 1613732A4 EP 20040758577 EP20040758577 EP 20040758577 EP 04758577 A EP04758577 A EP 04758577A EP 1613732 A4 EP1613732 A4 EP 1613732A4
Authority
EP
European Patent Office
Prior art keywords
biomarkers
intracellular complexes
intracellular
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20040758577
Other languages
German (de)
English (en)
Other versions
EP1613732A2 (fr
Inventor
Sharat Singh
M Youssouf Badal
Xuenguang Jin
Hossein Salimi-Moosavi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/623,057 external-priority patent/US7105308B2/en
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Publication of EP1613732A2 publication Critical patent/EP1613732A2/fr
Publication of EP1613732A4 publication Critical patent/EP1613732A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20040758577 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs Withdrawn EP1613732A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45988803P 2003-04-01 2003-04-01
US10/623,057 US7105308B2 (en) 2002-07-25 2003-07-17 Detecting receptor oligomerization
US49448203P 2003-08-11 2003-08-11
US50803403P 2003-10-01 2003-10-01
US51294103P 2003-10-20 2003-10-20
US52325803P 2003-11-18 2003-11-18
PCT/US2004/009805 WO2004087887A2 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs

Publications (2)

Publication Number Publication Date
EP1613732A2 EP1613732A2 (fr) 2006-01-11
EP1613732A4 true EP1613732A4 (fr) 2012-03-14

Family

ID=33136354

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20040758577 Withdrawn EP1613732A4 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs

Country Status (6)

Country Link
EP (3) EP1613732A4 (fr)
JP (2) JP2006521821A (fr)
AU (3) AU2004225439A1 (fr)
BR (3) BRPI0408950A (fr)
CA (3) CA2521082A1 (fr)
WO (3) WO2004087887A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
EP1613732A4 (fr) * 2003-04-01 2012-03-14 Monogram Biosciences Inc Complexes intracellulaires utilises comme biomarqueurs
CA2535510C (fr) 2003-08-11 2013-10-15 Monogram Biosciences, Inc. Detection et profilage de complexes moleculaires
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie
EP1805676A1 (fr) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Procedes et produits logiciels pour l'analyse et l'optimisation de marqueurs candidats pour le pronostic du cancer
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2008102A4 (fr) * 2006-04-18 2009-07-08 Wellstat Biologics Corp Detection de proteines dans des cellules neoplastiques en circulation
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2518508A1 (fr) 2006-11-28 2012-10-31 U3 Pharma GmbH HER3 activé servant de marqueur pour prédire l'efficacité thérapeutique
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BRPI0813583A2 (pt) * 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
EP2235536A4 (fr) 2007-12-20 2011-05-04 Lab Corp America Holdings Procédés de diagnostic du her-2
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
WO2009137664A1 (fr) * 2008-05-07 2009-11-12 Eutropics Pharmaceuticals, Inc. Anticorps spécifiques aux hétérodimères de la famille bcl-2 et leurs utilisations
WO2010019952A2 (fr) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Procédés, systèmes et produits pour prévoir une réponse de cellules tumorales à un agent thérapeutique, et traitement d'un patient selon la réponse prévue
SG177252A1 (en) 2008-12-01 2012-03-29 Lab Corp America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
CA2756493C (fr) 2009-03-24 2019-07-02 Biocept, Inc. Dispositifs et procedes de capture et d'analyse de cellules
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
EP2430443B1 (fr) 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarqueurs permettant de déterminer la sensibilité de cellules cancéreuses du sein à un traitement ciblant le récepteur her2
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2012135695A2 (fr) * 2011-03-30 2012-10-04 The Uab Research Foundation Modulation de migration cellulaire
WO2013033623A1 (fr) 2011-09-02 2013-03-07 Nestec S.A. Profilage de protéines de voie de signalisation pour déterminer une efficacité thérapeutique
IN2014DN11205A (fr) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
CA2908515A1 (fr) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systemes et procedes pour faciliter le diagnostic, le pronostic et le traitement d'un cancer sur la base de la detection de l'activation de her3
AU2014269946A1 (en) * 2013-05-21 2015-12-03 Nestec S.A. Methods for predicting and improving the survival of colorectal cancer patients
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
US10640803B2 (en) 2013-10-30 2020-05-05 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
EP3245301B1 (fr) 2015-01-12 2020-11-11 Eutropics Pharmaceuticals, Inc. Essai de diagnostic dépendant du contexte pour guider le traitement du cancer
WO2016127220A1 (fr) * 2015-02-13 2016-08-18 The University Of Queensland Procédés de classement des tumeurs et leurs utilisations
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161030A1 (fr) 2016-03-15 2017-09-21 Laboratory Corporation Of America Holdings Procédés d'évaluation d'interactions de protéines entre des cellules
WO2019098385A1 (fr) * 2017-11-20 2019-05-23 コニカミノルタ株式会社 Procédé d'évaluation de médicament
IT201800008274A1 (it) * 2018-08-31 2020-03-02 Alifax Srl Metodo immunometrico per analisi cliniche biologiche

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE162892T1 (de) 1992-07-31 1998-02-15 Behringwerke Ag Photoaktivierbare chemiluminizierende matrices
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5693271A (en) 1994-09-01 1997-12-02 Chase Industries, Inc. Rotationally molding an insulated plastic molded door with integral hinge
US5599631A (en) 1995-03-08 1997-02-04 Eastman Kodak Company Fluorinated elastomer/fluorinated resin compositions for toner fusing members
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6095661A (en) 1998-03-19 2000-08-01 Ppt Vision, Inc. Method and apparatus for an L.E.D. flashlight
JP2002534058A (ja) * 1998-09-08 2002-10-15 アグロン ファ−マシュ−テイカルズ インコ−ポレイテッド 脈管内皮成長因子レセプタ一２タンパクの修飾方法およびその使用方法
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
EP1305632B1 (fr) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methodes servant a la detection d'analytes multiples
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
US20020127654A1 (en) * 2001-02-22 2002-09-12 Price Virginia L. Compositions and methods for production cell culture
WO2002095356A2 (fr) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Procedes et compositions pour l'analyse de proteines
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
CA2354690A1 (fr) 2001-07-20 2001-10-27 Jan Prinzmetal Tapis
US6545102B1 (en) * 2001-09-27 2003-04-08 Lumigen, Inc. Polymer-supported photosensitizers
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004087887A2 *
SHINODA SACHIKO ET AL: "Interaction of 14-3-3 with Bid during seizure-induced neuronal death.", JOURNAL OF NEUROCHEMISTRY, vol. 86, no. 2, July 2003 (2003-07-01), pages 460 - 469, XP002667074, ISSN: 0022-3042 *
ZHA J ET AL: "Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL", CELL, CELL PRESS, US, vol. 87, 15 November 1996 (1996-11-15), pages 619 - 628, XP002110634, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(00)81382-3 *

Also Published As

Publication number Publication date
AU2004225439A1 (en) 2004-10-14
EP1613205B1 (fr) 2013-04-24
WO2004087887A2 (fr) 2004-10-14
AU2004230700A1 (en) 2004-10-28
CA2521106A1 (fr) 2004-10-14
JP2006523314A (ja) 2006-10-12
WO2004091384A3 (fr) 2005-12-29
EP1613961A4 (fr) 2007-03-07
BRPI0408961A (pt) 2006-10-31
AU2004229348A1 (en) 2004-10-28
WO2004092353A3 (fr) 2005-03-03
WO2004092353A2 (fr) 2004-10-28
EP1613961A2 (fr) 2006-01-11
WO2004087887A3 (fr) 2006-06-15
BRPI0408928A (pt) 2006-09-12
CA2521077A1 (fr) 2004-10-28
EP1613732A2 (fr) 2006-01-11
EP1613205A2 (fr) 2006-01-11
CA2521082A1 (fr) 2004-10-28
WO2004091384A2 (fr) 2004-10-28
BRPI0408950A (pt) 2006-03-28
JP2006521821A (ja) 2006-09-28
EP1613205A4 (fr) 2006-11-29

Similar Documents

Publication Publication Date Title
EP1613961A4 (fr) Complexes de recepteurs de surface utilises comme biomarqueurs
NL300885I2 (nl) Irinotecansucrosofaatzout
DE602004001908D1 (de) Kompressor
ATE453394T1 (de) Multipartikeln
EP1901702A4 (fr) Complexes ioniques
LU92427I2 (fr) Aripiprazole
IS8108A (is) Ný efnasambönd
DE502004003964D1 (de) Metallkomplexe
CR9080A (es) Compuestos sulfonamida
DK1581535T3 (da) Pyrrolopyridazinderivater
DE602004005498D1 (de) Fluoreffiziente appreturen für textilien
DE602004000230D1 (de) Verdichter
DE602004006755D1 (de) Kompressor
IS8228A (is) Ný asetídínefnasambönd
EP1703127A4 (fr) Compresseur
DE602004031650D1 (de) Drehbund für hubsäge
DE602004010443D1 (de) Kompressor
IS8292A (is) Ný efnasambönd
EP1640609A4 (fr) Compresseur
DE502004008685D1 (de) Fadenführervorrichtung für ringspindel
DE602004009257D1 (de) Bremsschlauchanordung
EP1650439A4 (fr) Compresseur
ITRM20040204A1 (it) Compressore alternativo.
FI20035051A0 (fi) Hakun vastaterä
FI5853U1 (fi) Vaappu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060817BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120210

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20120203BHEP

Ipc: G01N 33/574 20060101ALI20120203BHEP

Ipc: G01N 33/542 20060101ALI20120203BHEP

17Q First examination report despatched

Effective date: 20150326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171003